In brief: Psivida, Eqitx, Ellex, BRC, AFT
26 July, 2005 by Ruth BeranFollowing its recent Nasdaq listing, Psivida (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) has appointed the president and CEO of New Jersey-based Chugai Pharma USA, David J Mazzo, as a non-executive director.
Consolidation and review for Avastra
25 July, 2005 by Ruth BeranWith the suspension of its Australian BioWeld Tube clinical trial and the postponement of European clinical trails, the June quarter was one of consolidation and review for Sydney biomaterials company Avastra (ASX:AVS).
Progen offered $3.39 million AusIndustry grant
25 July, 2005 by Ruth BeranBrisbane cancer-drug developer Progen Industries (ASX:PGL, NASDAQ:PGLAF) has been offered and intends to accept a AUD$3.39 million AusIndustry "Commercial Ready" grant for further development of the company's drug discovery program over the next three years.
Compumedics earnings lower than anticipated
22 July, 2005 by Ruth BeranCompumedics' (ASX:CMP) has reported revenues of AUD$38 million for the 2004-2005 financial year, with the company's audited results anticipated to be released during the second half of August.
Visiomed awarded $40,000 in WA government funding initiative
22 July, 2005 by Helen SchullerPerth-based biomedical devices developer, Visiomed Group (ASX:VSG) has been awarded two Business Development and Skills Training Scheme (BDSTS) grants, worth a total of AUD$40,000 from the Western Australian Department of Industry and Resources.
Biosignal technology effective against microbrial corrosion
22 July, 2005 by Graeme O'NeillBacteria and fungi thrive in some of the most hostile environments on the planet, and employ exotic metabolic reactions to extract energy from the most toxic substrates -- including acidic industrial wastes and hydrocarbon fuels.
International linkage grants and international fellows announced
21 July, 2005 by Graeme O'NeillFederal science minister Dr Brendan Nelson announced today the government will provide AUD$2,972,440 to fund 42 new awards for Australian-based researchers to participate in joint research projects with their overseas peers in 18 different countries, under the Australian Research Council's Linkage International Scheme.
BresaGen nets $200,000 SA govt grant
20 July, 2005 by Helen SchullerBresaGen (ASX:BGN) has been awarded a Commercial Infrastructure Grant of AUD$200,000 from Bio Innovation SA, the South Australian government's biotechnology agency.
Chemeq subscribers agree to extend convertible bond completion date
20 July, 2005 by Ruth BeranFollowing a trading halt, Chemeq (ASX:CMQ) has updated the market on the allotment and issue of AUD$20 million additional convertible bonds to Japanese investment group Mizuho International and related entities of investment management group Stark Investments, due on July 15.
In brief: Chemeq, Acuron, Compumedics, Synchrotron
19 July, 2005 by Staff WritersChemeq (ASX:CMQ) is in a trading halt in the lead-up to an announcement concerning the underwriting of AUD$20 million convertible bonds to Mizuho International, Stark Trading and Shephard Investments International, to which it committed itself in April.
Locals win grants to study in US
19 July, 2005 by Helen SchullerFellowship grants of more than AUD$270,000 have been awarded to seven Australian scientists to pursue research and studies at American Institutions courtesy, of the American Australian Association.
Genesis Biomedical granted option to purchase NZ company
19 July, 2005 by Ruth BeranGenesis Biomedical (ASX:GBL) has been granted an option to purchase 100 per cent of the issued capital of privately owned New Zealand based Manawatu Biotech Investments (MBI).
Biosignal, US partner to work on biofilm apps
19 July, 2005 by Graeme O'NeillSydney anti-microbial developer Biosignal (ASX:BOS) has linked up with a major US-based technology evaluation corporation to assess the market potential of its furanone anti-biofilm technology.
Biomira exercises rights in Prima
18 July, 2005 by Ruth BeranCanadian-based cancer vaccine company Biomira has exercised its put option to take up equity in Prima Biomed (ASX:PRR) by swapping its 10 per cent equity in Prima's subsidiary company CancerVac for approximately 1.62 per cent equity in Prima.
FASTS critical of ARC board sacking
18 July, 2005 by Graeme O'NeillThe Federation of Australian Scientific and Technological Societies (FASTS) has criticised a decision by the Minister for Education, Science and Training, Dr Brendan Nelson, to dissolve the board of the Australian Research Council from early next year.
